GlobeNewswire by notified

Roche completes purchase agreement with long-term partner TIB Molbiol to expand PCR-test portfolio in the fight against new infectious diseases

Share
  • TIB Molbiol excels in ultra-rapid assay development for emerging infectious disease, strongly demonstrated during the COVID-19 pandemic
  • The acquisition enables Roche to further expand the portfolio of currently over 45 CE-IVD assays and more than 100 research use assays on Roche’s LightCycler PCR instruments
  • TIB Molbiol will continue to focus on the research and development of assays that rapidly address critical healthcare needs including biological threats

Basel, 1 December 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced it has completed its share purchase agreement to acquire 100 percent of the outstanding shares of TIB Molbiol Group. TIB Molbiol will continue to operate as a subsidiary within the Diagnostics division. Roche and TIB Molbiol will build on their capabilities for the rapid development of assays for emerging pathogens and potential health threats, such as infectious diseases.

With over 45 CE-IVD assays and more than a 100 research-use-only assays joining the Roche family, the companies will jointly accelerate access for patients around the world to even more clinically important diagnostic tests. TIB Molbiol will further expand Roche’s molecular diagnostics solutions, especially for the flexible open platforms LightCycler PCR and MagNA Pure sample preparation systems.

The two companies have collaborated for more than 20 years to rapidly address critical healthcare needs including biological threats, such as SARS, anthrax, avian influenza virus H5N1, MERS, the novel influenza virus H1N1 swine, Ebola virus, Zika virus and most recently, SARS-CoV-2 virus and its variants. For example, in 2001 with anthrax and 2003 with SARS-CoV1, TIB Molbiol demonstrated their ability to develop PCR assays for the detection of new pathogens within days.

“I am very pleased that together with TIB Molbiol, we can significantly improve access for patients to a broader spectrum of diagnostic tests - from high volume routine tests to the diagnosis of rare diseases. TIB Molbiol will continue to be an innovation engine and frontrunner in our common fight against infectious diseases, such as SARS-CoV-2”, said Thomas Schinecker, CEO Roche Diagnostics. “TIB Molbiol has helped to shape the future of PCR infectious disease testing, and will continue to drive cutting-edge research so we can bring better healthcare outcomes to patients faster.”

About TIB Molbiol
TIB Molbiol is a biotech company that has supplied the global market with reagents for research and medical diagnostics for over 30 years. As manufacturer of custom oligonucleotides the company partnered in the development of molecular diagnostics and built a broad portfolio of diagnostic assays, in particular for inherited genetic as well as somatic mutation testing, quantitative assays for haematology and transplantation medicine. The majority of assays are used to test for infectious diseases. They are available as modular kits, enabling the creation of symptomatic panels by combining assays, including emerging pathogens. To support customers performing human genotyping, TIB Molbiol provides custom made LightSNiP assays for SNP analysis. TIB Molbiol is headquartered in Berlin (Germany) and has local representations in Australia, Colombia, Italy, Spain and the US.

About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics, as well as growing capabilities in the area of data-driven medical insights help Roche deliver truly personalised healthcare. Roche is working with partners across the healthcare sector to provide the best care for each person.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. In recent years, the company has invested in genomic profiling and real-world data partnerships and has become an industry-leading partner for medical insights.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the thirteenth consecutive year, Roche has been recognised as one of the most sustainable companies in the pharmaceutical industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 58.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com

Dr. Nicolas Dunant
Phone: +41 61 687 05 17
Sileia Urech
Phone: +41 79 935 81 48

Dr. Barbara von Schnurbein
Phone: +41 61 687 89 67
Karsten Kleine
Phone: +41 61 682 28 31

Nina Mählitz
Phone: +41 79 327 54 74
Nathalie Meetz
Phone: +41 61 687 43 05

Roche Investor Relations

Dr. Karl Mahler
Phone: +41 61 68-78503
e-mail: karl.mahler@roche.com
Dr. Sabine Borngräber
Phone: +41 61 68-88027
e-mail: sabine.borngraeber@roche.com
Dr. Bruno Eschli
Phone: +41 61 68-75284
e-mail: bruno.eschli@roche.com

Dr. Birgit Masjost
Phone: +41 61 68-84814
e-mail: birgit.masjost@roche.com
Dr. Gerard Tobin
Phone: +41 61 68-72942
e-mail: gerard.tobin@roche.com
Investor Relations North America
Loren Kalm
Phone: +1 650 225 3217
e-mail: kalm.loren@gene.com

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Effnetplattformen Holding AB (publ): Effnet releases Effnet Backhaul Header Compression(TM) for VXLAN, PPP and PPPoE compression19.1.2022 15:07:14 CET | Press release

Luleå, 2022-01-19 -- Effnet AB, the leading provider of header compression software for wireless and fixed networks, today announced the release of Effnet Backhaul Header CompressionTM (Effnet BHCTM) for VXLAN compression, PPP compression and PPPoE compression. The VXLAN protocol is ubiquitously used in communication between disaggregated data centers. When such communication is made over links with limited bandwith, VXLAN compression is beneficial to increase the throughput and communication efficiency. PPPoE is commonly used for last mile connectivity (end-customers) over DSL, FTTx, HFC etc. On the customer side, it is implemented on the customer premises equipment (CPE) and on the service provider side, it is implemented on the DSLAM or an Optical Node. When the PPPoE tunnel is carried over links with limited or costly bandwidth, e.g., satellite or microwave links, Effnet BHCTM can save bandwidth and improve user experience. PPPoE is also used in core networks which can result in mu

mPrest Announces Expansion of Transformer Health Management Partnership with Energisa Group19.1.2022 14:00:00 CET | Press release

Following a successful year-long first phase, Energisa Group will continue to leverage mPrest’s mTHM platform to ensure the reliability and security of their energy supply across an expanded amount of system transformers CATAGUASES, Brazil and TEL AVIV, Israel, Jan. 19, 2022 (GLOBE NEWSWIRE) -- mPrest, a leading developer and provider of distributed asset orchestration and optimization software for the energy market, today announced the expansion of an ongoing partnership to provide further use of mPrest’s Transformer Health Management (mTHM) system to Energisa Group, a leading energy distribution group in Brazil. mTHM is part of mPrest’s Asset Performance Management system (APM), a holistic solution that supports a rich set of energy assets. This is the second phase of a deal between mPrest and Energisa to monitor and manage the health and reliability of Energisa’s power transformers and grid. Following the successful first phase of the partnership, which began one year ago and includ

RESULT RIKSBANK PURCHASES OF CORPORATE BONDS19.1.2022 11:30:00 CET | Press release

AuctionResult of auctionAuction date2022-01-19NameELLEVIO AB IsinXS1562583341Coupon, spread1.341Maturity2024-02-28Tendered volume, SEK mln30 +/- 30Offered volume, SEK mln-Volume bought, SEK mln-Number of bids-Number of accepted bids-Average yield, DM-Lowest accepted yield, DM-Highest yield, DM-Accepted at lowest yield, %- AuctionResult of auctionAuction date2022-01-19NameELLEVIO AB IsinXS1526292815Coupon, spread1.391 Maturity2023-12-09Tendered volume, SEK mln30 +/- 30Offered volume, SEK mln-Volume bought, SEK mln-Number of bids-Number of accepted bids-Average yield, DM-Lowest accepted yield, DM-Highest yield, DM-Accepted at lowest yield, %- AuctionResult of auctionAuction date2022-01-19NameFASTIGHETS AB BALDERIsinSE0011869825Coupon, spread1.477Maturity2024-06-05Tendered volume, SEK mln30 +/- 30Offered volume, SEK mln-Volume bought, SEK mln-Number of bids-Number of accepted bids-Average yield, DM-Lowest accepted yield, DM-Highest yield, DM-Accepted at lowest yield, %- AuctionResult of a

REC Silicon - New share capital registered19.1.2022 10:27:07 CET | Press release

(Oslo, Norway, 19 January 2022). Reference is made to the announcement by REC Silicon ASA (“REC Silicon” or the “Company”) published on 14 January 2022 regarding the board’s resolution to issue 48,213,001 new shares (the "New Shares") in the Company as a result of the agreement relating to a strategic equity investment in the Company by Hanwha Solutions Corporation.. The Share capital increase related to the New Shares has now been registered with the Norwegian Register of Business Enterprises. The new share capital of the Company is NOK 420,625,659, divided into shares 420,625,659, each with a par value of NOK 1. For further information, please contact: Douglas Moore, Chief Financial Officer Phone: +1 509 766-9133 Email: douglas.moore@recsilicon.com Nils O. Kjerstad IR Contact Phone: +47 9135 6659 Email: nils.kjerstad@crux.no. About REC Silicon REC Silicon is a leading producer of advanced silicon materials, delivering high-purity polysilicon and silicon gas to the solar and electroni

Acron Group’s Output Up 6% in 202119.1.2022 10:01:39 CET | Press release

19 January 2022 Acron Group’s Output Up 6% in 2021 The Group’s Consolidated Output (including operating results for Acron, Dorogobuzh, and North-Western Phosphorous Company) Product, ‘000 t20212020YOY, %MINERAL FERTILISERSAmmonia2,9092,7296.6%Incl. in-house consumption2,8452,617Nitrogen fertilisers, including5,0584,7077.5%Incl. in-house consumption921690AN2,2412,430-7.8%Incl. in-house consumption339213Urea1,4631,18023.9%Incl. in-house consumption582477Incl. prilled urea400485-17.5% Incl. in-house consumption1716Incl. granulated urea529261102.7% Incl. in-house consumption3226UAN1,3541,09623.5%Complex fertilisers, including2,6252,37210.7%Incl. in-house consumption6152NPK2,4062,2367.6%Incl. in-house consumption6152Bulk blends21913661.0%Total commercial output for Mineral Fertilisers6,7656,4484.9%INDUSTRIAL PRODUCTSOrganic compounds, including47442312.1%Incl. in-house consumption246213Methanol105987.7%Incl. in-house consumption9178Formalin16915112.4%Incl. in-house consumption150131Urea-for

Bavarian Nordic udnævner Russell Thirsk til ny Chief Operating Officer19.1.2022 09:13:24 CET | pressemeddelelse

KØBENHAVN, Danmark, 19. januar 2022 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at selskabet har udnævnt Russell Thirsk til Executive Vice President og Chief Operating Officer med virkning fra den 1. april 2022. Russell Thirsk overtager stillingen fra Henrik Birk, der har valgt at søge nye udfordringer. Timingen muliggør en smidig overdragelse af opgaverne fra Henrik Birk. Russell Thirsk kommer fra GSK, hvor han har været Head of Operations i GSK Vaccines i Belgien siden 2016. Denne stilling har han bestredet siden GSK’s opkøb af vaccineforretningen fra Novartis, hvor han arbejdede i mere end to årtier i ledende stillinger med stigende ansvar inden for vaccineproduktion i forskellige lande. Russell Thirsk er Master of Chemical Engineering fra University of Nottingham. “Jeg er glad for at byde Russell velkommen til Bavarian Nordic. Han vil bidrage med sin omfattende tekniske og ledelsesmæssige erfaring fra vaccineindustrien, hvor han har drevet flere komplekse anlægs- og transform

Bavarian Nordic Appoints Russell Thirsk as new Chief Operating Officer19.1.2022 09:13:24 CET | Press release

COPENHAGEN, Denmark, January 19, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today the appointment of Russell Thirsk as Executive Vice President and Chief Operating Officer, effective from April 1, 2022. Mr. Thirsk will take over this position from Henrik Birk, who has decided to seek new challenges outside Bavarian Nordic. The timing allows a period of handover from Henrik Birk to ensure a smooth transition. Mr. Thirsk joins Bavarian Nordic from GSK, where he has served as Head of Operations at GSK Vaccines in Belgium since 2016, a role he assumed after GSK’s acquisition of Novartis’ vaccine business, where he served for more than two decades, holding leadership roles of increasing responsibility in vaccine manufacturing operations across various geographies. Mr. Thirsk holds a Master of Chemical Engineering from University of Nottingham. “I am very pleased to welcome Russell to Bavarian Nordic. He brings extensive experience, both from a technical and a leadership perspective fr